Prevalence and incidence of juvenile idiopathic arthritis-associated uveitis and medication trends in the TriNetX database
Rayna Marshall, Jennifer Thorne, Meghan K BerkenstockAims
To investigate the prevalence and incidence of juvenile idiopathic arthritis (JIA)-associated uveitis (JIA-U) in the USA from 2013 to 2023 by analysing the TriNetX database. Secondary outcomes analysed included disease demographics, associated ocular complications and immunosuppressive prescription trends.
Methods
Patients with JIA-U were identified in the TriNetX database, a large, multicentre research network, through International Classification of Diseases, 10th Edition codes. Data collected included patient demographics, concurrent uveitic ocular complications, incidence, prevalence and cumulative prevalence of JIA-U in the 11-year period and immunosuppressive utilisation in the JIA population.
Results
4510 patients with JIA-U were included in this study. The cumulative prevalence and incidence of JIA-U over the 11-year period were 4.4 and 1.2 per 100 000 cases, both of which decreased over the study period. 5.5% of patients with JIA had a diagnosis of uveitis and 36.1% of patients with JIA-U had an associated uveitic ocular adverse event, including glaucoma, band keratopathy, low vision and blindness. The prevalence of immunosuppressive drug therapy in patients with JIA increased over the years 2013–2023.
Conclusion
In this large US database, the JIA-U prevalence and incidence rates decreased between 2013 and 2023. This may be partially attributed to the increasing prevalence of immunosuppressive drug use in patients with JIA.